Catalyst Calendar

Fri, Sep 25, 2026

1 updates

7:00 PM

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP -Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per

incyte.com

Tue, Sep 22, 2026

1 updates

INCY

8:30 AM

Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio

WILMINGTON, Del. --(BUSINESS WIRE)--Sep. 22, 2026-- Incyte (Nasdaq:INCY) today announced that data from across its Inflammation and Autoimmunity (IAI) portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 2026, held September 30 - October 3, 2026, in Vienna,

Presentation / Abstract • Phase 3EADV poster presentations Wed, Sep 30, 2026, 1:00 AM ETincyte.com

Tue, Sep 1, 2026

1 updates

INCY

8:00 AM

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del. --(BUSINESS WIRE)--Sep. 1, 2026-- Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: 21st Annual Wells Fargo Healthcare Conference on Wednesday, September 9, 2026 at 11:00 a.m.

incyte.com